Intra-Cellular Therapies Shares Outstanding 2013-2024 | ITCI

Intra-Cellular Therapies shares outstanding for the quarter ending June 30, 2024 were 0.104B, a 8.1% increase year-over-year.

  • Intra-Cellular Therapies 2023 shares outstanding were 0.096B, a 1.95% increase from 2022.
  • Intra-Cellular Therapies 2022 shares outstanding were 0.094B, a 15.75% increase from 2021.
  • Intra-Cellular Therapies 2021 shares outstanding were 0.081B, a 15.47% increase from 2020.

Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.

Intra-Cellular Therapies Shares Outstanding 2013-2024 | ITCI

  • Intra-Cellular Therapies 2023 shares outstanding were 0.096B, a 1.95% increase from 2022.
  • Intra-Cellular Therapies 2022 shares outstanding were 0.094B, a 15.75% increase from 2021.
  • Intra-Cellular Therapies 2021 shares outstanding were 0.081B, a 15.47% increase from 2020.

Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$178.8B
Regeneron Pharmaceuticals (REGN)$126.4B
Vertex Pharmaceuticals (VRTX)$124.2B
Gilead Sciences (GILD)$103.4B
Bristol Myers Squibb (BMY)$100.3B
CSL (CSLLY)$97.4B
GSK (GSK)$88.2B
Alnylam Pharmaceuticals (ALNY)$35.2B
Argenex SE (ARGX)$31.2B
BioNTech SE (BNTX)$29.7B
Biogen (BIIB)$28.9B
Moderna (MRNA)$27.7B
Illumina (ILMN)$20.7B
BeiGene (BGNE)$19.2B
Genmab (GMAB)$17.5B
BioMarin Pharmaceutical (BMRN)$13.4B
Vaxcyte (PCVX)$13B
Incyte (INCY)$12.8B
Insmed (INSM)$12.6B
Exact Sciences (EXAS)$12.6B
Sarepta Therapeutics (SRPT)$12B
Bio-Techne Corp (TECH)$11.9B
QIAGEN (QGEN)$10.4B
Legend Biotech (LEGN)$9.3B
Bio-Rad Laboratories (BIO.B)$9.1B
Roivant Sciences (ROIV)$8.9B
Ascendis Pharma (ASND)$8.5B
Exelixis (EXEL)$7.9B
Halozyme Therapeutics (HALO)$7.8B
Repligen (RGEN)$7.6B